Multiple clinical trials are currently recruiting participants to assess the effectiveness and the safe profile of EpCAM CAR-T cells in individuals with advanced HCC (NCT02729493), postoperative relapse (NCT03013712), and refractory HCC (NCT05028933). Here, EPCAM is linked to hepatocellular carcinoma.